ESPE Abstracts (2018) 89 P-P1-054

ESPE2018 Poster Presentations Diabetes & Insulin P1 (53 abstracts)

CpG Methylation Status Changes within the Protein Tyrosine Phosphatase Non-Receptor Type 22 Gene Promoters in Children and Adolescents of Greek Origin with Type 1 Diabetes

Konstantina Mouzaki a , Styliani Giza a , Eleni P. Kotanidou a , Aikaterini Fragou b , Maria Taousani b , Maria Eboriadou-Petikopoulou a , Georgios Tzimagiorgis b & Assimina Galli-Tsinopoulou a


a4th Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece; bLaboratory of Biological Chemistry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece


Introduction: Protein tyrosine phosphatase non-receptor type 22 (PTPN22) is a well-established genetic locus of type 1 diabetes (T1D). The aim of the present study is to compare the methylation level of PTPN22 between children and adolescents of Greek origin with T1D and healthy controls.

Patients and Methods: Twenty T1D participants and 20 age-/gender-matched healthy youngsters were enrolled. DNA was extracted from white blood cells, then treated with sodium bisulphate which converts unmethylated cytosines into uracyls, whereas methylated cytosines remain unchanged under the same conditions. DNA was then amplified by PCR using primers:(F) primer:5′TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTTTTGGTTTATGTTGTAGAGT3′ and (R) primer:5′GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTTACATATAAATAATA AAATAAAAT3′. Amplicons were analysed by electrophoresis (1% agarose gel stained with ethidium bromide), visualized by ultraviolet trans-illumination, and then Next Generation Sequencing was applied to identify differences in DNA methylation status. The methylation profile was analyzed at 4 CpG sites of the PTPN22 gene. Comparisons between groups were performed with student’s t-test or its non-parametric analogue, Mann Whitney U test, as appropriate.

Results: We found that the methylation level was statistically significant lower at position 1-4826 (P=0.026) in patients (0.35±0.17) compared to controls (0.52±0.28). Furthermore, there was a tendency for statistically significant hypomethylation at position 3-5018 (P=0.065) in patients (0.24±0.09) than in controls (0.30±0.13).

Table 1 4 CpGs in PTPN22 gene
DNA methylation (%) T1D (n=20)Controls (n=20)p
Overall mean methylation percentage
Mean methylation0.4±0.10.46±0.140.179
Range0–10–1
CpG sites
1-48260.35±0.170.52±0.280.026
2-49500.45±0.220.51±0.290.640
3-50180.24±0.090.30±0.130.065
4-50460.56±0.370.50±0.340.659
Results are expressed as Mean ± Standard Deviation.

Conclusion: To our knowledge, this is the first time to detect hypomethylation of PTPN22 gene in patients with T1DM.

Volume 89

57th Annual ESPE (ESPE 2018)

Athens, Greece
27 Sep 2018 - 29 Sep 2018

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.